Margaret McManus1, Brad Karalius2, Kunjal Patel2, Deborah Persaud3, Katherine Luzuriaga1,4. 1. Program in Molecular Medicine. 2. Department of Epidemiology and the Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health, Boston, Massachusetts. 3. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4. UMass Center for Clinical and Translational Science, University of Massachusetts Medical School, Worcester.
Abstract
OBJECTIVE: This study evaluated HIV-1 antibody levels as predictors of cell-associated HIV-1 DNA levels in perinatally infected (PHIV) children with long-term viral suppression on antiretroviral therapy (ART). DESIGN: HIV-1 antibody and HIV-1 DNA levels were measured in blood specimens from 61 children and adolescents from the Pediatric HIV/AIDS Cohort Study: Adolescent Master Protocol. Twenty perinatally HIV-1-exposed, uninfected children studied through 2 years served as controls. METHODS: HIV-1 IgG antibodies to six HIV-1 proteins were measured by quantitative ELISA; HIV-1 DNA levels were measured by droplet digital PCR. RESULTS: Among 13 children with viral suppression at less than 1 year, antibodies to gp160 and gp41 were low but stable longitudinally; antibodies to p17, p24, and RT decreased, and antibodies to p31 were low or undetectable. Among 48 children with viral suppression between 1 and 5 years, antibody levels to all six HIV-1 proteins were higher than in children with earlier viral suppression and remained high over time. A receiver operator curve approach identified gp41 and gp160 as useful predictors of HIV-1 DNA less than 10 or less than 100 copies per million PBMC (cpm); C-statistics including all antibodies ranged from 0.75 to 0.77. An ensemble learning approach also identified gp41 and gp160 as important predictors of HIV-1 DNA less than 10 or less than 100 cpm; area under the curve estimates utilizing all HIV-1 antibodies ranged from 0.70 to 0.81. CONCLUSION: Quantitative HIV-1 gp41 and gp160 antibody levels may serve as rapid, inexpensive screening tools for low PBMC HIV-1 DNA levels in children with viral suppression on ART, facilitating inclusion into remission protocols.
OBJECTIVE: This study evaluated HIV-1 antibody levels as predictors of cell-associated HIV-1 DNA levels in perinatally infected (PHIV) children with long-term viral suppression on antiretroviral therapy (ART). DESIGN: HIV-1 antibody and HIV-1 DNA levels were measured in blood specimens from 61 children and adolescents from the Pediatric HIV/AIDS Cohort Study: Adolescent Master Protocol. Twenty perinatally HIV-1-exposed, uninfected children studied through 2 years served as controls. METHODS: HIV-1 IgG antibodies to six HIV-1 proteins were measured by quantitative ELISA; HIV-1 DNA levels were measured by droplet digital PCR. RESULTS: Among 13 children with viral suppression at less than 1 year, antibodies to gp160 and gp41 were low but stable longitudinally; antibodies to p17, p24, and RT decreased, and antibodies to p31 were low or undetectable. Among 48 children with viral suppression between 1 and 5 years, antibody levels to all six HIV-1 proteins were higher than in children with earlier viral suppression and remained high over time. A receiver operator curve approach identified gp41 and gp160 as useful predictors of HIV-1 DNA less than 10 or less than 100 copies per million PBMC (cpm); C-statistics including all antibodies ranged from 0.75 to 0.77. An ensemble learning approach also identified gp41 and gp160 as important predictors of HIV-1 DNA less than 10 or less than 100 cpm; area under the curve estimates utilizing all HIV-1 antibodies ranged from 0.70 to 0.81. CONCLUSION: Quantitative HIV-1 gp41 and gp160 antibody levels may serve as rapid, inexpensive screening tools for low PBMC HIV-1 DNA levels in children with viral suppression on ART, facilitating inclusion into remission protocols.
Authors: Alfredo Tagarro; Man Chan; Paola Zangari; Bridget Ferns; Caroline Foster; Anita De Rossi; Eleni Nastouli; María A Muñoz-Fernández; Diana Gibb; Paolo Rossi; Carlo Giaquinto; Abdel Babiker; Claudia Fortuny; Riccardo Freguja; Nicola Cotugno; Ali Judd; Antoni Noguera-Julian; María Luisa Navarro; María José Mellado; Nigel Klein; Paolo Palma; Pablo Rojo Journal: J Acquir Immune Defic Syndr Date: 2018-10-01 Impact factor: 3.731
Authors: Deborah Persaud; Hannah Gay; Carrie Ziemniak; Ya Hui Chen; Michael Piatak; Tae-Wook Chun; Matthew Strain; Douglas Richman; Katherine Luzuriaga Journal: N Engl J Med Date: 2013-10-23 Impact factor: 91.245
Authors: Gert U van Zyl; Margaret A Bedison; Anita Janse van Rensburg; Barbara Laughton; Mark F Cotton; John W Mellors Journal: J Infect Dis Date: 2014-12-23 Impact factor: 5.226
Authors: Ari Bitnun; Lindy Samson; Tae-Wook Chun; Fatima Kakkar; Jason Brophy; Danielle Murray; Shawn Justement; Hugo Soudeyns; Mario Ostrowski; Shariq Mujib; P Richard Harrigan; John Kim; Paul Sandstrom; Stanley E Read Journal: Clin Infect Dis Date: 2014-06-09 Impact factor: 9.079
Authors: Deborah Persaud; Kunjal Patel; Brad Karalius; Kaitlin Rainwater-Lovett; Carrie Ziemniak; Angela Ellis; Ya Hui Chen; Douglas Richman; George K Siberry; Russell B Van Dyke; Sandra Burchett; George R Seage; Katherine Luzuriaga Journal: JAMA Pediatr Date: 2014-12 Impact factor: 16.193
Authors: Margaret McManus; Eric Mick; Richard Hudson; Lynne M Mofenson; John L Sullivan; Mohan Somasundaran; Katherine Luzuriaga Journal: PLoS One Date: 2016-04-22 Impact factor: 3.240
Authors: Avy Violari; Mark F Cotton; Louise Kuhn; Diana B Schramm; Maria Paximadis; Shayne Loubser; Sharon Shalekoff; Bianca Da Costa Dias; Kennedy Otwombe; Afaaf Liberty; James McIntyre; Abdel Babiker; Diana Gibb; Caroline T Tiemessen Journal: Nat Commun Date: 2019-01-24 Impact factor: 14.919
Authors: Margherita Doria; Sonia Zicari; Nicola Cotugno; Sara Domínguez-Rodríguez; Alessandra Ruggiero; Giuseppe R Pascucci; Alfredo Tagarro; Pablo Rojo Conejo; Eleni Nastouli; Kathleen Gärtner; Mark Cameron; Brian Richardson; Caroline Foster; Sion L Williams; Stefano Rinaldi; Anita De Rossi; Carlo Giaquinto; Paolo Rossi; Savita Pahwa; Paolo Palma Journal: J Int AIDS Soc Date: 2021-07 Impact factor: 5.396